Literature DB >> 7917683

Peripheral vascular disease: consequence for survival and association with risk factors in the Speedwell prospective heart disease study.

D Bainton1, P Sweetnam, I Baker, P Elwood.   

Abstract

OBJECTIVE: To measure the prevalence and incidence of intermittent claudication, to describe the mortality associated wtih the condition, and to assess the relevance of risk factors for vascular disease.
DESIGN: A standard questionnaire on calf pain when walking was given in the prospective Speedwell study, and a range of risk factors were measured. The men were re-examined at intervals of three years, and deaths over 11 years were identified.
SETTING: The general population. PARTICIPANTS: All men aged 45 to 59 registered with 16 general practitioners.
RESULTS: The prevalence of intermittent claudication increased from almost nil at ages 45-49 to 2.9% at ages 60-64. The annual incidence increased from 0.3% in the youngest men to 0.5% in those in their early 60s. Intermittent claudication was related to the existence of ischaemic heart disease, particularly angina, at the first examination. The relative odds of men with angina developing intermittent claudication was 6.7 (95% confidence interval (95% CI) 3.6 to 12.4). The risk of death in men with intermittent claudication was substantially raised. After standardisation for age and smoking the relative odds of death was 3.8 (95% CI 2.2 to 6.5). The excess was entirely from circulatory causes. Systolic blood pressure, fasting plasma glucose, triglycerides, and white cell count were all independently associated with the development of intermittent claudication, but the most striking association was with smoking.
CONCLUSIONS: Intermittent claudication is an indicator for a very high risk of death. This is only partly explained by its strong association with ischaemic heart disease.

Entities:  

Mesh:

Year:  1994        PMID: 7917683      PMCID: PMC1025474          DOI: 10.1136/hrt.72.2.128

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  13 in total

1.  Intermittent claudication, heart disease risk factors, and mortality. The Whitehall Study.

Authors:  G D Smith; M J Shipley; G Rose
Journal:  Circulation       Date:  1990-12       Impact factor: 29.690

2.  Mortality over a period of 10 years in patients with peripheral arterial disease.

Authors:  M H Criqui; R D Langer; A Fronek; H S Feigelson; M R Klauber; T J McCann; D Browner
Journal:  N Engl J Med       Date:  1992-02-06       Impact factor: 91.245

3.  The Framingham Study. Cigarettes and the development of intermittent claudication.

Authors:  W B Kannel; D Shurtleff
Journal:  Geriatrics       Date:  1973-02

4.  Intermittent claudication. Incidence in the Framingham Study.

Authors:  W B Kannel; J J Skinner; M J Schwartz; D Shurtleff
Journal:  Circulation       Date:  1970-05       Impact factor: 29.690

5.  Self-administration of a questionnaire on chest pain and intermittent claudication.

Authors:  G Rose; P McCartney; D D Reid
Journal:  Br J Prev Soc Med       Date:  1977-03

6.  Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study.

Authors:  F G Fowkes; E Housley; R A Riemersma; C C Macintyre; E H Cawood; R J Prescott; C V Ruckley
Journal:  Am J Epidemiol       Date:  1992-02-15       Impact factor: 4.897

7.  Intermittent claudication: prevalence and risk factors.

Authors:  W G Hughson; J I Mann; A Garrod
Journal:  Br Med J       Date:  1978-05-27

8.  Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population.

Authors:  F G Fowkes; E Housley; E H Cawood; C C Macintyre; C V Ruckley; R J Prescott
Journal:  Int J Epidemiol       Date:  1991-06       Impact factor: 7.196

9.  Update on some epidemiologic features of intermittent claudication: the Framingham Study.

Authors:  W B Kannel; D L McGee
Journal:  J Am Geriatr Soc       Date:  1985-01       Impact factor: 5.562

10.  Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. The Caerphilly and Speedwell collaborative heart disease studies.

Authors:  J W Yarnell; I A Baker; P M Sweetnam; D Bainton; J R O'Brien; P J Whitehead; P C Elwood
Journal:  Circulation       Date:  1991-03       Impact factor: 29.690

View more
  16 in total

1.  Peripheral vascular disease: consequence for survival and association with risk factors in the Speedwell prospective heart disease study.

Authors:  H Khaira; P Tisi; C Shearman
Journal:  Br Heart J       Date:  1995-02

Review 2.  Peripheral arterial disease, type 2 diabetes and postprandial lipidaemia: Is there a link?

Authors:  Pedro Valdivielso; José Ramírez-Bollero; Carmen Pérez-López
Journal:  World J Diabetes       Date:  2014-10-15

3.  The association between thrombotic and inflammatory biomarkers and lower-extremity peripheral artery disease.

Authors:  Savas Celebi; Berkten Berkalp; Basri Amasyali
Journal:  Int Wound J       Date:  2020-05-22       Impact factor: 3.315

4.  Lipoprotein Particle Profiles, Standard Lipids, and Peripheral Artery Disease Incidence.

Authors:  Aaron W Aday; Patrick R Lawler; Nancy R Cook; Paul M Ridker; Samia Mora; Aruna D Pradhan
Journal:  Circulation       Date:  2018-11-20       Impact factor: 29.690

5.  Differential effect of female gender on coronary artery disease and peripheral artery disease.

Authors:  H W O Roeters van Lennep; H T Westerveld; A H Zwinderman; J E Roeters van Lennep; H Bruins Slot; D W Erkelens; E E van der Wall
Journal:  Neth Heart J       Date:  2002-12       Impact factor: 2.380

6.  Angina pectoris is a stronger indicator of diffuse vascular atherosclerosis than intermittent claudication: Framingham study.

Authors:  W B Kannel; J C Evans; S Piper; J M Murabito
Journal:  J Clin Epidemiol       Date:  2008-05-20       Impact factor: 6.437

7.  Intermittent claudication: From its risk factors to its long-term prognosis in men. The Quebec Cardiovascular Study.

Authors:  A St-Pierre; B Cantin; B Lamarche; D Auger; Jean- Pierre Després; G R Dagenais
Journal:  Can J Cardiol       Date:  2010-01       Impact factor: 5.223

8.  Vascular disease, ESRD, and death: interpreting competing risk analyses.

Authors:  Morgan E Grams; Josef Coresh; Dorry L Segev; Lauren M Kucirka; Hocine Tighiouart; Mark J Sarnak
Journal:  Clin J Am Soc Nephrol       Date:  2012-08-02       Impact factor: 8.237

Review 9.  Homocysteine lowering interventions for peripheral arterial disease and bypass grafts.

Authors:  Alina Andras; Gerard Stansby; Monica Hansrani
Journal:  Cochrane Database Syst Rev       Date:  2013-07-19

10.  The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases.

Authors:  J Danesh; S Erqou; M Walker; S G Thompson; R Tipping; C Ford; S Pressel; G Walldius; I Jungner; A R Folsom; L E Chambless; M Knuiman; P H Whincup; S G Wannamethee; R W Morris; J Willeit; S Kiechl; P Santer; A Mayr; N Wald; S Ebrahim; D A Lawlor; J W G Yarnell; J Gallacher; E Casiglia; V Tikhonoff; P J Nietert; S E Sutherland; D L Bachman; J E Keil; M Cushman; B M Psaty; R P Tracy; A Tybjaerg-Hansen; B G Nordestgaard; R Frikke-Schmidt; S Giampaoli; L Palmieri; S Panico; D Vanuzzo; L Pilotto; L Simons; J McCallum; Y Friedlander; F G R Fowkes; A J Lee; F B Smith; J Taylor; J Guralnik; C Phillips; R Wallace; D Blazer; K T Khaw; J H Jansson; C Donfrancesco; V Salomaa; K Harald; P Jousilahti; E Vartiainen; M Woodward; R B D'Agostino; P A Wolf; R S Vasan; M J Pencina; E M Bladbjerg; T Jorgensen; L Moller; J Jespersen; R Dankner; A Chetrit; F Lubin; A Rosengren; L Wilhelmsen; G Lappas; H Eriksson; C Bjorkelund; P Cremer; D Nagel; R Tilvis; T Strandberg; B Rodriguez; L M Bouter; R J Heine; J M Dekker; G Nijpels; C D A Stehouwer; E Rimm; J Pai; S Sato; H Iso; A Kitamura; H Noda; U Goldbourt; V Salomaa; J T Salonen; K Nyyssönen; T-P Tuomainen; D Deeg; J L Poppelaars; T Meade; J Cooper; B Hedblad; G Berglund; G Engstrom; A Döring; W Koenig; C Meisinger; W Mraz; L Kuller; R Selmer; A Tverdal; W Nystad; R Gillum; M Mussolino; S Hankinson; J Manson; B De Stavola; C Knottenbelt; J A Cooper; K A Bauer; R D Rosenberg; S Sato; Y Naito; I Holme; H Nakagawa; H Miura; P Ducimetiere; X Jouven; C Crespo; M Garcia-Palmieri; P Amouyel; D Arveiler; A Evans; J Ferrieres; H Schulte; G Assmann; J Shepherd; C Packard; N Sattar; B Cantin; B Lamarche; J-P Després; G R Dagenais; E Barrett-Connor; D Wingard; R Bettencourt; V Gudnason; T Aspelund; G Sigurdsson; B Thorsson; M Trevisan; J Witteman; I Kardys; M Breteler; A Hofman; H Tunstall-Pedoe; R Tavendale; G D O Lowe; Y Ben-Shlomo; B V Howard; Y Zhang; L Best; J Umans; A Onat; T W Meade; I Njolstad; E Mathiesen; M L Lochen; T Wilsgaard; J M Gaziano; M Stampfer; P Ridker; H Ulmer; G Diem; H Concin; F Rodeghiero; A Tosetto; E Brunner; M Shipley; J Buring; S M Cobbe; I Ford; M Robertson; Y He; A M Ibanez; E J M Feskens; D Kromhout; R Collins; E Di Angelantonio; S Kaptoge; S Lewington; L Orfei; L Pennells; P Perry; K Ray; N Sarwar; M Scherman; A Thompson; S Watson; F Wensley; I R White; A M Wood
Journal:  Eur J Epidemiol       Date:  2007-09-18       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.